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Abstract 
Background. Hereditary hemochromatosis (HH) is the most common form of genetic 
iron loading disease. It is mainly related to the HFE C282Y/C282Y homozygous 
genotype that is however a necessary but not a sufficient condition to develop clinical 
and even biochemical HH. This suggests that modifiers genes are likely involved in 
the expressivity of the disease. Our aim was to identify such modifier genes. 
Patients and methods. We performed a genome-wide association study (GWAS) 
using DNAs collected from 474 unrelated C282Y homozygotes. Associations were 
examined for both quantitative iron burden indices and clinical outcomes with 
534,213 single nucleotide polymorphisms (SNP) genotypes, with replication analyses 
in an independent sample of 748 C282Y homozygotes from four different European 
centres.  
Results. One SNP met genome-wide statistical significance for association with 
transferrin concentration (rs3811647, GWAS p-value of 7×10−9 and replication p-
value of 5×10−13). This SNP located within intron 11 of TF gene had pleiotropic effect 
on serum iron (GWAS p-value of 4.9×10−6 and replication p-value of 3.2×10−6). Both 
serum transferrin and iron levels were associated with serum ferritin levels, amount of 
iron removed and global clinical stage (p<0.01). Serum iron levels were also 
associated with fibrosis stage (p<0.0001). 
Conclusion. This GWAS, the largest one performed so far in unselected HFE-HH 
patients, identified the rs3811647 polymorphism in the TF gene as the only SNP 
significantly associated with iron metabolism through serum transferrin and iron 
levels. Because these two outcomes were clearly associated with the biochemical 
and clinical expression of the disease, an indirect link between the rs3811647 
polymorphism and the phenotypic presentation of HFE-HH is likely.  
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Introduction 
 
Genetic hemochromatoses are hereditary disorders proceeding from impairment in 
the production and/or activity of the key regulator of plasma iron, hepcidin, and 
resulting in progressive iron loading of parenchymas. HFE-hemochromatosis 
accounts for more than 95% of genetic hemochromatosis cases in Caucasian 
populations [1]. It is chiefly related to one major mutation, p.Cys282Tyr (C282Y), 
whose frequency ranges from 5% to 15% according to an increasing gradient from 
South/East to North/West but whose penetrance is far from complete [2]. 
 
Large studies based on systematic genotyping of large populations [2-6] have 
consistently found that transferrin saturation and serum ferritin levels, the key 
biochemical markers of genetic hemochromatosis, were significantly increased in 
C282Y homozygotes when compared to sex-matched controls with other HFE 
genotypes. According to studies, the percentage of C282Y homozygous subjects 
with elevated transferrin saturation ranged from 73 to 84% in males compared to 40 
to 73% in females. The same was found for serum ferritin levels with a prevalence of 
increased values ranging from 70 to 88% in males and 33 to 69% in females. As a 
whole, the biochemical penetrance of C282Y in homozygotes can be estimated as 
about 75% in males and 50% in females. However, only a few studies of the clinical 
expressivity of C282Y homozygotes achieved a sufficient statistical power and 
referred to a control group to allow for a correct interpretation of the data. [2,5,7-9] 
Based on these studies, it can be concluded that the clinical expressivity of the 
C282Y homozygous genotype is indisputably much lower than previously admitted, 
averaging 28% in males and 1% in females when using strict definitions of both iron 
overload and iron-related organ damage [2]. The main manifestations of HFE-
hemochromatosis are chronic fatigue, arthritis and liver disease. The frequency of 
heart disease and diabetes are not significantly increased in C282Y homozygotes 
compared with controls [1]. However fatigue and arthritis are not clearly correlated 
with the amount of iron burden. With respect to liver disease, serum ferritin levels 
lower than 1000µg/L allow exclusion of significant fibrosis, as demonstrated by 
Guyader et al [10] and confirmed by Allen et al [2]. Thus C282Y homozygosity 
appears to be a necessary but not a sufficient condition for the development of HFE-
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hemochromatosis and the existence of both environmental and genetic modifiers of 
its penetrance is strongly suggested. 
 
Although familial studies have shown that non-HFE iron-related genes are involved in 
the modulation of iron burden in C282Y homozygotes, only a few putative genetic 
modifiers have been identified so far in humans. A mitochondrial polymorphism has 
been reported as more frequent in iron loading expressing than in non-expressing 
C282Y homozygotes [11] but this was not confirmed by another study [12]. Co-
inheritance of mutations in the hepcidin gene (HAMP) [13,14] or in the hemojuvelin 
gene (HFE2) [15] together with C282Y homozygosity was found to be associated with 
more severe iron burden of earlier onset in a French cohort of C282Y homozygotes 
[13,15]. However these mutations have a frequency lower than 2‰ among C282Y 
homozygotes and can thus explain increased disease severity in a few patients only. 
Based on these results, the BMP - SMAD pathway regulating hepcidin production 
was highlighted as an important pathway that was likely including potential modifying 
genes. This was confirmed by the finding, in a large cohort of C282Y homozygotes, 
of an association between common variants in the BMP pathway and the level of iron 
burden [16,17]. The full expression of HFE-hemochromatosis may thus be linked to 
abnormal hepatic expression of hepcidin, through both impairment in HFE function 
and functional modulation in the BMP pathway. Other results support the hypothesis 
that polymorphisms in different genes regulating iron metabolism may modulate 
penetrance of HFE-HH. CYBRD1 was shown to be a possible modifier gene of iron 
phenotype in patients with HFE-HH [18,19] and, recently, the p.Ala736Val TMPRSS6 
polymorphism was shown to be likely a modifier of HFE-HH in a highly selected 
subgroup of male C282Y homozygotes [20]. 
 
We hypothesized that other common variants located in genes outside this pathway 
could modulate iron overload in HFE-HH. To identify these variants, we conducted a 
genome-wide association study in 518 C282Y homozygous HFE-HH patients from 
the tertiary referral centre of Rennes, France. The association between SNPs and 7 
clinical and biochemical outcomes was examined and a replication study of candidate 
SNPs was conducted in a sample of 748 HFE-HH patients from 4 Italian and French 
centres. In this paper, we present the results of this GWAS study that is the largest 
conducted so far in HFE-HH patients.  
  

  
	
Materials and Methods 
 
Study population and replication sample 
 
Approval for the genome-wide association study was obtained from the local ethical 
committee (reference 09/10-722 – 23/03/2009). All participants gave written informed 
consent. Samples were collected thanks to the Logifer database comprising all 
C282Y homozygous probands and relatives referred to the Liver Unit in Rennes, 
France, and collected retrospectively before 1989 and, then, prospectively. According 
to French rules, Logifer was declared to the national committee “Informatics and 
Freedom” (CNIL). Data are recorded from patient’s files by data-managers and 
keyboarded twice. A clinical research assistant provides quality control, and 
coherence control and statistical analysis are performed by a bio-statistician. 
 
Selection criteria included availability of sex, age at diagnosis, serum ferritin level at 
diagnosis before any venesection therapy, amount of iron removed by phlebotomy 
and frozen DNA samples stored at -20°C in the Centre of Biological Resources of 
Rennes. Carriers of the H63D mutation were excluded from this study. Of the 1730 
C282Y homozygotes recorded in Logifer at the time of the study, 518 fulfilled these 
criteria. Replication for SNPs identified from the GWAS was conducted in 748 C282Y 
homozygous patients with informed consent from four different European Centres: 
Toulouse in Southern France (n=279), Brest and Rennes in Brittany (n=226 and 
n=124, respectively), and Monza in Northern Italy (n=119). Seven clinical and 
biochemical outcomes were examined: serum transferrin concentration, serum iron, 
serum ferritin, transferrin saturation, amount of iron removed by phlebotomy, liver 
fibrosis, and mixed biochemical and clinical score referred as the HAS score (Haute 
Autorité de Santé) [21]. All clinical and biochemical data were recorded at the time of 
diagnosis before any venesection therapy. Table 1 presents the characteristics of all 
the samples included in the GWAS and replication studies. 
 
Liver fibrosis was assessed using the Metavir scoring system when liver biopsy was 
available (n=227) [22]. Patients were classified as having severe fibrosis when the 
Metavir score was either F3 or F4. In the absence of liver biopsy, according to 
Guyader’s algorithm, severe liver fibrosis was considered as absent when serum 
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ferritin was < 1000 µg/L. HAS score [21] ranged from 0 to 4 according to the 
absence/presence of increased transferrin saturation (stage 1), elevated serum 
ferritin levels (stage 2), iron-related functional symptoms (asthenia, distal arthralgia; 
stage 3) and iron-related organ damage (liver fibrosis, diabetes; stage 4). In addition, 
the following data, recorded at the time of diagnosis, were available for the Rennes 
GWAS cohort: alcohol consumption, tobacco smoking, medicinal iron and drug 
intake, year(s) and number of blood donations, year(s) and number of pregnancies, 
age at menopause, weight and height, blood pressure, common blood tests including 
serum cholesterol, triglycerides, ASAT, ALAT, glucose, uric acid, creatinine, and HCV 
antibody and HBs antigen (negative in all patients).  
 
Laboratory Methods 
 
We determined iron status by measuring the levels of serum iron (mmol/L), 
transferrin saturation with iron (%) and serum ferritin (µg/L). Amount of iron removed 
(g) was assessed from the volume of blood extracted during initial depletion therapy 
until the achievement of low body iron stores (serum ferritin  50), assuming that 500 
ml of blood contains 250 mg of elemental iron. For patients that were not subject to 
phlebotomy because of the absence of significant iron overload, it was assumed to 
be 0. Genomic DNA was extracted from peripheral blood cells by the phenol-
chloroform method or by use of the Flexigen DNA kit (Qiagen). Only DNA samples 
with quality in accordance with Illumina recommendations were kept. 
 
Genome-wide genotyping and quality control procedures 
 
GWAS was performed on the 518 cases with the Illumina™ InfiniumHD technology 
(Human660W-Quad). A total of 657,366 markers were assessed for quality. Quality 
control tests were carried out using the GenABEL library [23] of the R statistical 
package (http://www.r-project.org/). The quality control flow diagram is presented in 
supplementary Fig. 1. Quality control assessments resulted in the exclusion of 
95,988 CNV markers and 27,165 SNPs because of at least one of the following 
criteria: a minor allele frequency less than 1%, a call rate less than 95%, or rejection 
of Hardy-Weinberg equilibrium (HWE) at p-value equal to 10-6. Thirty-one samples 
were excluded from the analysis due to a call rate <99%, too high autosomal 
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heterozygosity (FDR <1%), an average identity-by-state (IBS) value > 0.2, or 
misclassification of sex. Iterative principal component analyses (PCA) of a matrix of 
IBS distances computed from the SNP genotype data excluded 13 patients as 
heterogeneous in ancestry or outliers. After filtering of SNPs and samples, there were 
534,213 SNPs available for analysis in a sample of 474 cases. Genetic population 
structure was assessed by PCA thanks to the OriginMineR R package. [24] 
 
Genotyping and quality control procedures for replication samples 
 
Replication for SNPs identified from the GWAS was carried out by custom Fluidigm 
SNPtype assays based on allele-specific PCR SNP detection chemistry and 
designed for the BioMark HD System. Each sample was assessed for completeness 
of data (>90%) and genotype data were assessed for deviation from HWE (p<10-6), 
minor allele frequency (>5%) and completeness (>99%). 
 
Statistical analyses  
 
Statistical analyses of the GWAS genotype data were carried out using the GenABEL 
R library for genome-wide association analysis [23]. The quantitative iron status 
outcomes were analysed using linear regression after rank-based inverse normal 
transformation to avoid inflated type I error resulting from departure from normality. 
Genotypes were coded as 0, 1 or 2, indicating the number of copies of the less 
frequent of the two alleles in the genotype. The regression models for all outcomes 
included the additive genotype term and the covariates: age, with consideration of 
age groups of 10 years, and sex. Population stratification was also taken into account 
by adjusting models for the two principal components obtained from the PCA of the 
whole genotype data. For liver fibrosis, logistic regression was performed and we 
used ordered logistic regression (R cran function, polr) to model HAS-score. For the 
replication phase, a four-level factor indicating the centre where the sample was 
collected was added to each model instead of the principal components. As we 
conducted several analyses using different phenotypes and performed 8 * 534,213 
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tests in our entire GWA analysis, we considered p-values < 10-8 (0.05/4.3 × 106) to 
indicate genome-wide significance in our study. 
The 20 SNPs tested in the replication study consisted of (i) SNPs with P<10-6 from 
which only two SNPs were selected by LD block (Table 2), and, (ii) SNPs with P<10-5 
and P>10-6 with one SNP being selected for each LD block to avoid redundancy 
(Supplementary Table 1). 
 
Genotype imputation 
 
Data were imputed for over 10 million SNPs using data from the 1000 Genomes 
Project [25]. Genotypes were aligned to the positive strand in both imputation and 
genotyping. SHAPEIT2 [26] and IMPUTE2 [27] were used for imputation of non-
genotyped SNPs in the Illumina Human660W-Quad chips. We removed SNPs with 
minor allele frequency less than 1% and impute info measure less than 0.8. Genome-
wide association analyses were conducted using SNPtest [27]. 
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Results 
 
Characteristics of patients 
The clinical and biological characteristics of patients belonging to the primary and 
replication cohorts are reported in Table 1. With respect to primary cohort, additional 
descriptive data were as follows:  BMI (men: 25.15±3.27, women: 24.25± 4.5), 
excessive alcohol consumption (men: 16%, women: 5%), tobacco consumption 
(men: 31%, women:15%), blood donation (men: 23%, women: 21%), proportion of 
pregnancies (none=17%, one or 2: 37%, greater than 3: 24.5%) , number of 
menopausal women (44%). Link between biological iron data and these putative 
modifying factors was investigated using both univariate and multivariate Gaussian 
regression models. Alcohol consumption was strongly associated with body iron 
(p=0.004) and serum ferritin (p=6x10-7) in univariate analyses. This association 
remains significant only with serum ferritin in a multivariate analysis including gender 
and age. In women, pregnancy and menopause were associated with body iron 
(p=0.04 and p=0.02, respectively), serum ferritin (p=0.04 and p=0.01, respectively) 
and serum iron (NS and p=0.002, respectively) in univariate analyses only. Thus, 
GWAS was performed with regression including age and sex as only covariates. For 
ferritin, an analysis including also alcohol consumption was performed. 
 
Genome-wide Association Study 
The sequencing of the HFE gene confirmed that all participants were homozygous for 
the p.Cys282Tyr mutation and did not carry any other mutation in this gene known to 
be involved in HH. Following quality control, a total of 534,213 SNP and 474 patients 
were included in the GWAS (supplementary Fig. 1). All HFE-HH patients were 
identified as being from European ancestry and particularly from Western Europe 
(supplementary Fig. 2).  
Figure 1 shows the Manhattan plot obtained for GWAS of all the seven clinical and 
biochemical outcomes. P-values <10-6 were obtained for ten SNPs on chromosomes 
2, 3, 6, 16 and 9 (Table 2) and 41 SNPs were found associated with at least one of 
the seven outcomes with p-values between 10-6 and 10-5 (Supplementary Table 1 
and Supplementary Fig. 3).  However, GWAS analyses identified only one locus 
reaching the genome-wide significance threshold of 10-8 (Figure 2). This locus 
associated with serum transferrin concentration was located on chromosome 3q22 
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(TF gene; rs3811647, intron 11, p-value = 7×10−9). This SNP was also associated 
with serum iron (p-value = 4.9×10−6) but not associated with other phenotypic 
descriptors. The effect of rs3811647 was additive with each A allele increasing both 
serum transferrin and serum iron concentration. It explained 7.7% of the variance of 
serum transferrin concentration and 4.7% of the variance of serum iron levels. Other 
potential associations were found between serum ferritin and rs3849200 on 
chromosome 6p16.3 (p-value = 6.2×10−7) and rs4544229 on chromosome 16q21 (p-
value = 8.9×10−7), between the amount of iron removed and rs4371141 (VAV2 gene) 
on chromosome 9q34 (p-value = 9.4×10−7), and between the HAS-score and 
rs3900546 located between LOC644013 and MAP4K4 on chromosome 2 (p-value = 
2×10−7). Associations between serum ferritin and rs3849200 and rs4544229 were 
conserved when alcohol consumption was included in the regression model. 
 
Follow-up Association Study 
 
In the second phase, twenty SNPs were selected for validation on an independent 
sample of 748 patients. Iron parameters distributions for patients included in the 
replication study are presented Table 1. Data distributions were compared between 
centres with linear models adjusted by age and gender (Supplementary Fig. 4). Raw 
iron parameters were found to vary significantly between centres (Supplementary 
Fig. 4 and 5A) but differences between centres were clearly reduced after rank-based 
inverse normal transformations (Supplementary Fig. 5B). After quality controls, a total 
of 18 SNPs were retained for replication, rs3849200 and rs2810493 being removed 
because of no call rate. Among these SNPs, only rs3811647 in the TF gene showed 
evidence for association with both serum transferrin and serum iron with p-values of 
5x10-13 and 3.6x10-6, respectively (Supplementary Table 2).  
 
Association Analysis of Combined GWAS and Follow-up Samples 
 
The GWAS and follow-up study data were combined (n=1220 patients) and were 
analysed for each outcome in a model that included age, sex, the collection centre 
variable and a variable to indicate if patients were from the GWAS or the follow-up 
study. Results are presented in Supplementary Table 3. Genome-wide significance 
was found for the association of rs3811647 in the TF gene with serum transferrin (p-
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value = 1×10−20) and serum iron (p-value = 9.24×10−11). Besides these strong 
associations, no significant direct association with other phenotypic descriptors was 
found. Four other loci show potential association signals but with low significance (p-
value around 10−3): rs10788066, located between the PPAPDC1A and SEC23IP 
genes, with serum ferritin, amount of iron removed, severe liver fibrosis, and HAS-
score; rs2941832, near the gene SALL3, with serum ferritin and amount of iron 
removed; rs2810473 and rs4406471 in the VAV2 gene with serum ferritin and, to a 
lesser extent, amount of iron removed, and rs17012214, located within the gene 
TTC27, with severe liver fibrosis. 
 
As the role of TMPRSS6 has been highly documented in iron metabolism in the last 
few years [29-33], we also assessed, in the combined cohort, the association of the 7 
outcomes with two common variants in TMPRSS6 (rs855791 and rs4820268). Using 
the same models, we found weak signals of association with the HAS-score for both 
SNPs (rs855791, p-value = 1×10−4 and rs4820268, p-value = 6×10−4), and with the 
amount of iron removed for rs4820268 only (p-value = 4×10−4). No association was 
detected with other parameters of iron status.  
 
rs3811647 genotypes in the general population 
We investigate the frequency of rs3811647 alleles from genotyping data obtained in 
a non-HFE population from Brittany (n=191). We found that A allele has frequency of 
0.343 (AA, n=21; AG, n=89; GG, n=81). We compared allele frequency in the 
population of C282Y homozygous patients against this population of Brittany and 
against GBR and CEU from 1000 Genomes and did not find any difference (chi-
squared test). 
 
Clinical, biochemical, and rs3811647 genotype correlations 
 
Clinical and biochemical parameters were investigated in relation with rs3811647 
genotypes in patients included in the GWAS study. Except for the additive effect of 
rs3811647, with each A allele increasing both serum transferrin and serum iron 
concentration, no significant influence of the rs3811647 genotype on clinical and 
other biochemical parameters was found (Table 3a). However, significant positive 
associations were detected between serum transferrin and serum iron levels and 
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between serum iron levels and all phenotypic outcomes studied. Serum transferrin 
levels were negatively correlated with all other phenotypic markers except fibrosis 
(Table 3b).  
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Discussion 
 
In this paper, we report the first study designed at the genome-wide scale to identify 
SNPs associated with clinical and biochemical expression of HFE-hemochromatosis. 
This study was performed in a large sample of well-defined C282Y homozygous 
patients, totalizing more than 1,200 individuals presenting with a wide range of 
phenotypic expression. No significant association was found between SNPs and 
clinical outcomes. With respect to biochemical outcomes, only one chromosomal 
region including the rs3811647 SNP in the TF gene showed clear evidence for 
association with serum transferrin in the GWAS (p-value=7×10−9), in the replication 
study (p-value=5x10-13) and the combined analysis (p-value=1×10−20). Unexpectedly, 
this SNP was also clearly associated with serum iron, and therefore indirectly linked 
to biochemical and clinical outcomes.  
 
Notably, in the general population, rs3811647 was reported as associated with serum 
transferrin but not with serum iron [33-35] contrary to what we found in 
hemochromatosis patients. It is possible that, in the general population, the power of 
detecting association with serum iron was compromised by the limited range of the 
values of this parameter. In contrast, our sample of C282Y homozygotes is a 
combination of biochemically expressing and non-expressing individuals. The 
necessarily wider range of serum iron in these patients may have allowed us to 
highlight the role of rs3811647 genotype in modulating not only serum transferrin but 
also serum iron levels.  
 
However, our study did not find a direct link between the rs3811647 SNP in the TF 
gene and the phenotypic presentation of HH. Indeed, although this SNP was 
associated with serum iron, it was not significantly associated with serum ferritin, 
transferrin saturation, or any of the clinical outcomes tested. Indirect tests of 
associations are less powered than direct tests and may require much larger sample 
sizes than the ones used in this study to allow us to demonstrate a possible influence 
of the genotype at rs3811647 on other parameters of disease severity. However, we 
cannot exclude that such an association exists in HFE hemochromatosis only 
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through the dysregulation of iron cellular efflux secondary to the impairment of 
hepcidin expression (Figure 3). 
 
Our study indicates that the association of rs3811647 with serum transferrin 
concentration is maintained in C282Y homozygous patients and that the lowest 
serum transferrin levels are observed in those bearing the GG genotype. However, 
even the patients with the rs3811647 AA genotype have less serum transferrin than 
normal controls polymorphism (data not shown). This finding fits with the common 
observation of decreased serum transferrin levels in C282Y homozygotes, which is 
attributed to the preservation of a physiologic negative feedback of transferrin 
synthesis by elevated body iron stores. This could contribute to aggravate the iron 
burden through the increase of transferrin saturation and the consecutive increase of 
non-transferrin bound iron, which is considered as the main factor of visceral iron 
loading in hemochromatosis. However, although they had lower serum transferrin 
levels, patients with the rs3811647 GG genotype had no increased transferrin 
saturation when compared to other patients.  This is in line with the concomitant 
decrease in serum iron levels, and could suggests that transferrin levels, as 
determined by rs3811647 polymorphisms, may participate per se in the regulation of 
systemic iron, possibly through a direct interaction with the molecular cascade 
involved in hepcidin production. [37] 
 
We took advantage of this study to investigate putative candidate genes selected 
from literature and/or coding for molecules involved in iron-related metabolic 
pathways and previously identified GWAS-significant SNPs (Supplementary Table 4 
and Supplementary Table 5). No association, even borderline, was found. Finally, we 
focused on TMPRSS6, a modifier gene identified by Valenti et al. in a highly selected 
population of 96 non-alcoholic male C282Y homozygotes [20]. In the subset of 230 
non-alcoholic male C282Y homozygotes from the GWAS sample, an association was 
detected with SNPs located in this gene at the 1% nominal level (p-value = 0.006 
with AIR), but this association did not resist multiple testing corrections at the 
genome-wide level. It remains possible that TMPRSS6 acts as a modifier-gene but 
with a weak effect compared to age and sex.  HH is a long-standing disease whose 
diagnosis is made at adulthood. Along the constitution of iron excess, many factors 
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are able to act, at various periods and in opposite directions, resulting in highly 
variable iron burden from an individual to another. These factors include, apart blood 
donation, pregnancies and menopause that are easy to take into account and to 
quantify, regimen, drugs (including iron auto-medication), menstrual blood loss, 
alcohol consumption and evolution of metabolic features that are difficult to reliably 
assess over a long period. This highlights the need for better controlling 
environmental factors, not only alcohol consumption, which implies to study much 
larger population than in the present GWAS. 
 
The present study suffered from several limitations. First, the phenotypic description 
of HH remains difficult and imprecise. Two types of indicators are available: those 
measuring the iron burden and those assessing organ damage. The degree of iron 
burden is usually deduced, at the time of diagnosis, from serum ferritin levels, hepatic 
iron concentration assessed either by biochemical determination or magnetic 
resonance imaging, histological semi-quantitative evaluation of hepatic iron stores, 
and, to a lesser extent, transferrin saturation. However, all these indicators have to 
be interpreted according to age and gender and are subject to frequent limitations. 
Conditions that often coexist in hemochromatosis and may result in overestimation of 
iron burden can modify serum ferritin levels (i.e. excessive alcohol intake, metabolic 
syndrome, cell necrosis and inflammatory syndrome). Because it requires an invasive 
approach, histological and biochemical determination of hepatic iron concentration is 
less and less performed.  It also depends on both liver volume and hepatic iron 
distribution that may be heterogeneous, especially in case of cirrhosis. Hepatic iron 
concentration measurement by MRI is reliable within the range of 60-300 µmol/g of 
dry liver only, which precludes correct assessment of iron burden in patients with 
early and late hemochromatosis. Finally, transferrin saturation is a rough indicator of 
iron burden because it is usually rapidly complete regardless of excess iron amount. 
Then, we chose to select only patients with amount of iron removed (AIR) available, 
since AIR is considered as the most reliable means to assess iron burden. However, 
because AIR is retrospective and often difficult to calculate, numerous C282Y 
homozygotes of the cohort were lost for inclusion. Indicators of organ damage allow 
for a precise case description, but the non-specificity of most clinical symptoms and 
high prevalence of co-damaging factors, such as metabolic syndrome and alcohol, 
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may result in overestimating the role of iron in the clinical presentation. Second, the 
present study may have been underpowered due to the limited number of cases for a 
GWAS (n = 474 from the 518 eligible cases) and to the few participants with low or 
normal body iron stores. Because the frequency of HFE C282Y homozygotes is very 
low, collecting enough sample size for such a study design to detect variants with 
moderate effect size is a challenge. Alternative strategy might be needed, such as 
conducting GWAS of iron status in the general population and then test the identified 
loci in the C282Y homozygous patients. Large genome-wide studies in which the 
authors looked for loci controlling serum iron, serum transferrin, transferrin saturation 
and serum ferritin in the general population have been published recently [33-35]. 
Although performed on large sample sizes, these studies did not provide evidence for 
variants with significant effects on any of the parameters examined, except for 
variants in the HFE and TMPRSS6 genes that were controlling serum iron, and 
variants in TF that were controlling serum transferrin. In this study we found that, in 
addition to being associated with serum transferrin, the same variants in the TF gene 
were also associated with serum iron in hemochromatosis patients. If we consider 
less stringent p-values, the variants in TMPRSS6 can also be considered as 
marginally associated with some of the iron burden parameters in this sample of 
hemochromatosis patients. The success rate of this strategy is therefore quite good, 
but there were not many variants segregating with iron burden in the general 
population. In addition, it is also possible that different variants control iron 
parameters in the general population and in hemochromatosis patients, which 
motivated this particular study. Unfortunately, the C282Y mutation is not routinely 
screened in the general population, and only few participants with low or normal 
parameters of iron burden are included in our GWAS study. Therefore, the power of 
this study is probably compromised to some extent by the limited range of expression 
of these parameters. Although large-scale studies in the general population could 
help identify such C282Y homozygotes with low or normal iron parameters, it should 
be remembered that the frequency of this genotype is only 3-5/1000, and obtaining a 
number of non-penetrant cases from the same area sufficient to increase the power 
of this study is unrealistic for the moment. The third limitation is the lack of suitable 
information about environmental factors. For example, data on regimen with respect 
to daily iron intake and tea consumption were missing in the database. However, 
data on alcohol consumption, tobacco smoking, blood donation, and, in females, 
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number of pregnancies and menopause status were collected and analyzed. We did 
not find significant association when taking alcohol consumption into account but 
samples sizes were probability too small to detect possible gene-environment 
interactions. Fourth, although a large number of SNPs were tested (n = 534,213), the 
present study was far from covering all putative genetic variants able to act as 
modifiers of iron burden and/or organ damage. Using the SNP-chip data, we 
investigated the possible role of CNV and did not find any association. However, we 
were not able to investigate low frequency and rare variants that are not targeted nor 
tagged by the SNP-chip. We thus cannot exclude based on our results the 
involvement of one or more modifier genes but we can rule out the role of common 
variants with large effect outside the TF gene. 
 
In conclusion, our results indicate that, in C282Y/C282Y HFE-HH, the rs3811647 
polymorphism in the TF gene continues to regulate serum transferrin levels and is 
unexpectedly associated with serum iron levels. Our study also demonstrates a 
potential indirect but weak link, through serum iron levels, between the rs3811647 
polymorphism and the clinical and biological expression of the disease. Finally it 
shows, by contrast to candidate gene studies, that, in an unselected and large 
population of C282Y homozygotes, i.e. in “true life”, there is no other common 
polymorphism exerting a significant phenotypic effect. At this stage, the role of rare 
and low frequency variants that are not tagged by SNP-chips remains to be 
investigated. Next-generation sequencing technologies will enable to explore their 
role and determine if there exist some rare mutations with clinical significance in 
HFE-HH. In designing exome or whole genome sequencing studies, it will however 
be important to carefully select patients  and to control for environmental factors.   
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Tables 
 
Table 1 – Main clinical and demographic characteristics of the primary and 
replication cohorts 
  GWAS sample 
Replication  samples 
Rennes Toulouse Brest Monza 
Sample size 474 124 279 224 119 
Gender (female) (male) (200)(274) (67)(57) (108)(171) (93)(133) (26)(93) 
Age at diagnosis (years) 45±12 44±14.2 47±12 46.0±13 45±12.2 
Serum iron (mmol/l) 34.5 (29 -  39.3) 34.00 (29.34 -  38.90) 35.6 (30.4 - 40.8) 36.0 (31.0 - 41.0) 36.43(33.48 - 39.55) 
NA’s 26 11 44 16 0 
Serum Transferrin (g/L) 1.80  (1.60-2.00) 1.88  (1.60-2.01) 1.78  (1.60-2.03) 1.77 (1.60-2.00) 1.83  (1.58-2.06) 
NA’s 38 14 55 16 0 
Transferrin saturation 
(%) 80 (65 - 89) 78 (66.5 - 85.85) 84 (67 - 92) 83 (73 - 92) 84 (72 - 90) 
NA’s 28 10 35 0 33 
AIR (g) 4.7 (2.1 - 8.2) 3.8 (1.7 - 7.8) 6.1 (3.5 - 11.2) 4.1 (2.12 - 6.8) 6(4 - 10.75) 
NA’s 0 0 197 0 0 
Serum ferritin (µg/L) 776 (446 - 1565) 570 (318 - 1136) 1118 (634 - 2315) 688 (370 - 995) 1120 (719-2374) 
NA’s 11 5 0 0 0 
Fibrosis (grading) 
  
   
  
no 367 100 128 161 81 
severe 72 14 30 41 25 
NA’s 35 10 121 22 13 
HAS (grading) 
0 13 3 3 0 1 
1 44 12 10 0 3 
2 131 45 89 0 48 
3 164 32 141 0 39 
4 76 18 36 0 28 
NA’s 46 14 0 224 0 
a Median value ± sd. 
b Median value (25th–75th percentile). 
* Amount of Iron Removed (weekly or bimonthly venesections until serum ferritin < 50; 1 L of blood = 0,5 g of iron) 
NA = non available 
 
Table 2. GWA Analyses results  with P-values <10-6 
SNP Trait Chr Position Closest gene Location A1 A2 maf N effB Pvalue Geno1.freq Geno2.freq Geno3.freq Replication 
rs2692695 sTF 3 134968144 TF intron G A 0.41 437 -0.35 1.85E-07 A/A: 78   G/A:230   G/G:166   NA 
rs3811647 sTF 3 134966719 TF intron G A 0.33 437 0.41 7.00E-09 A/A: 46   G/A:217   G/G:211   X 
rs6794945 sTF 3 135001153 SRPRB flanking_5UTR G A 0.3 437 0.38 6.03E-07 A/A: 33   G/A:219   G/G:222   NA 
rs3849200 sFRT 6 101765612 GRIK2 flanking_5UTR G A 0.1 463 0.44 6.19E-07 A/A:  5   G/A: 88   G/G:381   X 
rs4371141 sFRT 16 57773110 GOT2 flanking_5UTR G A 0.19 463 0.34 9.43E-07 A/A: 18   G/A:144   G/G:312   X 
rs4544229 sFRT 16 57786093 GOT2 flanking_5UTR G A 0.19 463 0.34 8.91E-07 A/A: 18   G/A:143   G/G:313   X 
rs2810472 AIR 9 135750460 VAV2 intron A G 0.25 472 -0.31 9.79E-07 A/A:271   A/G:170   G/G: 33   NA 
rs2810473 AIR 9 135750672 VAV2 intron G A 0.25 472 -0.31 9.79E-07 A/A: 33   G/A:170   G/G:271   X 
rs2810493 AIR 9 135756956 VAV2 intron G A 0.27 472 -0.3 9.44E-07 A/A: 36   G/A:181   G/G:257   X 
rs3900546 HAS 2 101560458 FLJ42986 flanking_5UTR A C 0.26 474 -0.75 2.00E-07 A/A:265   A/C:170   C/C: 39   X 
Abbreviations: sTF=serum transferrin concentration, sFRT= serum ferritin concentration, AIR= amount of iron removed, HAS= 
HAS score, A1= reference allele, A2: non-reference allele, maf=minor allele frequency, effB= Effect of the non-reference allele 
in allelic test. 
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Table 3. rs3811647 genotypes, clinical and biochemical correlations 
a. 
rs3811647 Serum iron Serum transferrin Transferrin 
saturation 
 Serum 
ferritin 
 Iron 
removed Fibrosis HAS score 
AA 38.8 ± 9.1 1.98 ± 0.30 78.3 ± 17.4 1632 ± 1646 7.3 ± 6.2 0.18 ± 0.38 2.66 ± 1.03 (n=43) (n=43) (n=44) (n=45) (n=45) (n=40) (n=44) 
AG 34.3 ± 9.1 1.87 ± 0.28 74.7 ± 18.8 1145 ± 1329 5.9 ± 4.9 0.14 ± 0.35 2.56 ± 1.03 (n=207) (n=198) (n=203) (n=213) (n=210) (n=198) (n=201) 
GG 32.4 ± 7.1 1.74 ± 0.33 75.9 ± 17.8 1296 ± 1356 6.7 ± 6.1 0.16 ± 0.36 2.56 ± 0.99 (n=98) (n=195) (n=199) (n=205) (n=201) (n=194) (n=200) 
 p<0.001 p<0.001 p=0.453 p=0.08 p=0.188 p=0.844 p=0.837 
 
b. 
Phenotypic 
markers Serum iron Serum transferrin 
Transferrin 
saturation 
 Serum 
ferritin 
 Iron 
removed Fibrosis HAS score 
Serum iron   r = 0.257 (n=436) p<0.0001 
r = 0.747 
(n=437) 
p<0.0001 
r = 0.279 
(n=445) 
p<0.0001 
r = 0.216 
(n=430) 
p<0.0001 
r = 0.165 
(n=411) 
p=0.0008  
r = 0.346 
(n=424) 
p<0.0001 
Serum 
transferrin 
r = 0.257 (n=436) 
p<0.0001   
r = - 0.388   
(n=436)     
p<0.0001 
r = - 0.081 
(n=433) 
p<0.0001 
r = -0.123 
(n=419) 
p=0.0118 
r = - 0.025 
(n=402) 
p=0.6115 
r = - 0.126 
(n=414) 
p=0.0104 
Transferrin 
saturation 
r = 0.747 (n=437) 
p<0.0001 
r = - 0.388          
(n=436)      
p<0.0001 
  
r = 0.347 
(n=443) 
p<0.0001 
r = 0.339 
(n=429) 
p<0.0001 
r = 0.197 
(n=410) 
p=0.0001 
r = 0.437 
(n=424) 
p<0.0001 
Correlations between semi-quantitative variables (fibrosis and HAS score) and quantitative variables 
were also performed using one-way analysis of variance and gave the same results. 
 
  

Figure Legends 
Figure 1 - Manhattan plots displaying results from GWAS of quantitative iron 
burden indices and clinical outcomes of HFE-HH.  
Genome-wide analyses were performed for quantitative iron burden indices (serum 
transferrin concentration, serum iron, transferrin saturation, amount of iron removed 
by phlebotomy, and serum ferritin), and clinical outcomes (severe liver fibrosis, and 
HAS-score). All the analyses were performed on 534,213 genotyped SNPs. 
Horizontal lines indicate a suggestive p-value threshold of 10-6.  
 
Figure 2 – Regional plots for rs3811647 located within TF gene. 
Regional plots for imputed results are presented for rs3811647 identified as the 
single locus reaching the genome-wide significance threshold of 10-8: for A. serum 
transferrin concentration analysis (p-value = 7 ×10-9), and B. with pleiotropic effect on 
serum iron (p-value = 4.9 ×10-6).  The rs3811647 SNPs is represented as a diamond. 
Other SNPs are gray scaled following their r2 value with the most associated SNP. 
The blue line represents variation in recombination rate. Plots were generated by 
LocusZoom. [28] 
 
Figure 3 – Regulation of hepcidin transcription through the bone 
morphogenetic protein (BMP) – Smad pathway. 
Binding of holotransferrin to transferrin receptor 1 (TfR1) displaces HFE from TfR1 to 
TfR2. The HFE-TfR2 complex binds to a complex associating BMPs, BMP receptor 
(BMPR) and hemojuvelin (HJV). Neogenin and transmembrane serine protease 6 
(TMPRSS6) modulate hepcidin transcription by cleaving HJV. Hepcidin acts by 
favoring the internalization and degradation of the transmembrane iron transporter, 
ferroportin (FRP), which results in decreasing the systemic biodisponiblity of iron. In 
HFE hemochromatosis, the C282Y mutation impairs the migration of HFE to the cell 
membrane and thus the activation of the BMP – BMPR- HJV complex. This results in 
the preservation of FRP at the cell membrane and thus a high iron efflux. [36] 
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